Herbal or natural medicines as modulators of peroxisome proliferator-activated receptors and related nuclear receptors for therapy of metabolic syndrome

被引:77
作者
Huang, THW
Kota, BP
Razmovski, V
Roufogalis, BD
机构
[1] Univ Sydney, Fac Pharm, Herbal Med Res & Educ Ctr, Sydney, NSW 2006, Australia
[2] Univ Sydney, Fac Pharm, Pharmaceut Chem Discipline, Sydney, NSW 2006, Australia
关键词
D O I
10.1111/j.1742-7843.2005.pto960102.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The use of herbal or natural medicines for the treatment of various disorders has a long and extensive history. Many of these herbal medicines are finding their way onto the world market as alternatives to prescribed drugs currently available to treat various disorders/ailments. In particular, hyperlipidaemia is a major risk factor for atherosclerotic coronary vascular disease, which can culminate in mortality in diabetes mellitus. There is overwhelming evidence that patients with type 2 diabetes mellitus often have metabolic syndrome and require a multifactorial intervention including aggressive treatment of arterial hypertension and dyslipidaemia to prevent cardiovascular complications. One of the most active areas of metabolic research into potential treatments is in the role of nuclear receptors as therapeutic targets for both glucose and lipid metabolism. The purpose of this review is to highlight the recent advances made by pharmaceutical and research organizations in identifying biologically active compounds from natural plant products capable of modulating nuclear receptors such as peroxisome proliferator-activated receptors and, to a lesser extent, liver X receptor and farnesoid X receptor. The specific features presented by these receptors provide an in-depth insight into the pathogenesis of metabolic disease and thus, a means of establishing potential mechanisms of action with traditional medicine. In hindsight, the review offers valuable information for rational drug design using known active compounds of plant origin. Further research may ultimately lead to a reduction in both the chronic microvascular complications of type 2 diabetes mellitus and the risk of cardiovascular disease and metabolic syndrome with the use of traditional medicine.
引用
收藏
页码:3 / 14
页数:12
相关论文
共 67 条
[1]  
Alzahrani T, 2003, CAN J CARDIOL, V19, P1499
[2]   Pharmacotherapy for dyslipidaemia - current therapies and future agents [J].
Bays, H ;
Stein, EA .
EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (11) :1901-1938
[3]  
Bays HE, 2003, BR J DIABETES VASC D, V3, P356, DOI DOI 10.1177/14746514030030050801
[4]   Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation [J].
Bishop-Bailey, D ;
Wray, J .
PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2003, 71 (1-2) :1-22
[5]  
Bocher Virginie, 2002, Journal de la Societe de Biologie, V196, P47
[6]   A natural product ligand of the oxysterol receptor, liver X receptor [J].
Bramlett, KS ;
Houck, KA ;
Borchert, KM ;
Dowless, MS ;
Kulanthaivel, P ;
Zhang, YY ;
Beyer, TP ;
Schmidt, R ;
Thomas, JS ;
Michael, LF ;
Barr, R ;
Montrose, C ;
Eacho, PI ;
Cao, GQ ;
Burris, TP .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 307 (01) :291-296
[7]   Detection of weak estrogenic flavonoids using a recombinant yeast strain and a modified MCF7 cell proliferation assay [J].
Breinholt, V ;
Larsen, JC .
CHEMICAL RESEARCH IN TOXICOLOGY, 1998, 11 (06) :622-629
[8]   Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus [J].
Brunzell, JD ;
Ayyobi, AF .
AMERICAN JOURNAL OF MEDICINE, 2003, 115 :24-28
[9]   Antioxidant and prooxidant behavior of flavonoids: Structure-activity relationships [J].
Cao, GH ;
Sofic, E ;
Prior, RL .
FREE RADICAL BIOLOGY AND MEDICINE, 1997, 22 (05) :749-760
[10]   Antidiabetic and hypolipidemic activity of Helicteres isora in animal models [J].
Chakrabarti, R ;
Vikramadithyan, RK ;
Mullangi, R ;
Sharma, VM ;
Jagadheshan, H ;
Rao, YN ;
Sairam, P ;
Rajagopalan, R .
JOURNAL OF ETHNOPHARMACOLOGY, 2002, 81 (03) :343-349